BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx and ...
FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...
The FDA approved Foundation Medicine’s cancer gene test Thursday. CMS also proposed national coverage of the test for Medicare beneficiaries with advanced cancer. The FoundationOne CDx is an in vitro ...
First and only company with 100 approved and active companion diagnostic indications for next-generation sequencing in the United States and Japan, setting the standard for high-quality genomic ...
Boca Raton, Fla.-based Cancer Treatment Centers of America and Foundation Medicine are collaborating on an educational campaign to raise awareness regarding the potential of precision medicine.
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results